SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (6837)7/29/1998 12:05:00 PM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
Bob, looks like you did all that road work for nothing. Richard Harmon must have been wearing his Sunday pants and didn't want to get them dirty. Have to admit though Little Richard is good in the idle gossip category.
To: Robert K. (5388 )
From: Richard Harmon Wednesday, Jul 29 1998 11:36AM ET
Reply # of 5390

Bob:

I answered your question. I said "To answer your question directly...... I don't know". Prophylaxis of sepsis is a more promising ballpark than the venue for previous XOMA efforts, and, as I've said many times and IMO, the trials are well designed and conceived. Let's hope that the results of the trauma trial are positive.

You want an answer outside of the context of the company/management, XOMA's current market cap, risk:reward ratio relative to other biotechs, etc. You now have such. I have long traded the issue with marked success, and I hope to continue to do such.

Good luck.

Rick





To: aknahow who wrote (6837)7/30/1998 2:38:00 AM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
CHECK THIS OUT GEORGE

NASD Member Firm: FIERO BROTHERS INC.
BD Number: 27269

6/04/98 SUMMARY INFORMATION

6/04/98: 2/06/98 PENDING NASD COMPLAINT

THE NASD FILED A COMPLAINT AGAINST FIERO BROTHERS INC. AND OTHER RESPONDENTS ALLEGING VIOLATIONS OF NASD RULES 2110, 2120, 3110 AND 3370 IN THAT THE FIRM AND OTHER RESPONDENTS, ENGAGED IN MANIPULATIVE CONDUCT IN VIOLATION OF SECTION 10(b) OF THE SECURITIES EXCHANGE ACT OF 1934, AND RULE 10b-5 THEREUNDER THROUGH COLLUSION, AND ENGAGING IN A MANIPULATIVE "BEAR RAID" TO DRIVE DOWN THE PRICE OF 10 NASDAQ SECURITIES UNDERWRITTEN BY A DEFUNCT BROKER/DEALER. THE RESPONDENTS, ACTING THROUGH THEIR OWN PROPRIETARY TRADING AND MARKET MAKING ACCOUNTS, AND IN CONJUNCTION WITH OTHERS, ENGAGED IN A MONTH-AND-A-HALF LONG PROGRAM OF SHORT SELLING THESE SECURITIES AND PARTICIPATED IN THE PROMULGATION OF NEGATIVE STORIES ABOUT THE FIRM AND CERTAIN OF THE SECURITIES OVER A NATIONALLY-TELEVISED CABLE BROADCAST; FIERO BROTHERS AND OTHER RESPONDENTS, ENGAGED IN SHORT SALES IN PROPRIETARY ACCOUNTS WHILE NOT REGISTERED AS A MARKET MAKER AND WITHOUT THE REQUISITE AFFIRMATIVE DETERMINATION REQUIREMENT. [PENDING NASD COMPLAINT NO. CAF980002]mm




To: aknahow who wrote (6837)7/30/1998 12:48:00 PM
From: Howard Henick  Read Replies (2) | Respond to of 17367
 
The problem with that statement is that it has been true for well over 5 years. What has to happen for investors to notice is a biotech company has to have earnings or at least a large drug close to approval like Immunex. Three drugs in phase 2 trials gets you bupkis!!!